CSF Proteomic Characterization of Glioblastomas

Launched by UNIVERIDAD AUTONOMA DE GUADALAJARA · Feb 21, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "CSF Proteomic Characterization of Glioblastomas," is designed to study glioblastomas, which are aggressive brain tumors. The main goal is to identify specific proteins present in the cerebrospinal fluid (the fluid that surrounds the brain and spinal cord) of patients with these tumors. By analyzing these proteins, researchers hope to find patterns that may help predict how long patients can live without their disease worsening and how well they can function.

To participate, individuals must be at least 18 years old and have a confirmed diagnosis of glioblastoma. Participants will undergo standard procedures, including a lumbar puncture to collect cerebrospinal fluid, a blood draw, and a tissue sample from the brain tumor. The study will involve follow-up appointments every three months for the first year after surgery. This trial is not yet recruiting participants, but it offers a chance for those diagnosed with glioblastoma to contribute to important research that could improve understanding and treatment of this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with confirmed diagnosis of glioblastoma (histopathological and molecular).
• • Patients who voluntarily accept participation in this study.
• • Patients aged 18 or older.
• Exclusion Criteria:
• • Patients who cannot be followed up at the Regional Hospital 'Dr. Valentin Gomez Farias' ISSSTE.
• • Contamination of the required sample (CSF, serum, tumor).
• • Patients with whom no sampling was obtained or subjects with incomplete background information.
• • Patients who decide to withdraw participation from the study.